References
- Briggs F. N., Munson P. L. Studies on the mechanism of stimulation of ACTH secretion with the aid of morphine as a blocking agent. Endocrinology 1955; 57: 205–219
- Gillies G., Linton E., Lowry P. J. Corticotrophin releasing activity of the new CRF is potentiated several times by vasopressin. Nature 1982; 229: 355–357
- Grossman A., Besser G. M. Opiates control ACTH through a noradrenergic mechanism. Endocrinology 1982; 17: 287–290
- Grossman A., Rees L. H. The neurology of opioid peptides. British Medical Bulletin 1983; 39: 83–88
- Lotti V. J., Kokka N., George R. Pituitary adrenal activation following intrahypothalamic microinjection of morphine. Neurology 1969; 4: 326–332
- Sandyk R. The opioid-noradrenergic link in Tourette's syndrome. Clinical Pharmacy 1985; 4: 502
- Sandyk R., Iacono R. P., Crinnian C., Bamford C. R., Consroe P. Effects of naltrexone in Tourette's syndrome. Annals of Neurology 1986; 20: 437
- Spiler I. J., Molitch M. E. Lack of modulation of pituitary hormone stress response by neural pathways involving opiate receptors. Journal of Clinical Endocrinology and Metabolism 1980; 50: 516–520
- Strahlendorf H. K., Strahlendorf S., Barnes C. D. Stimulation of hypothalamic arcuate nulceus inhibits locus coeruleus activity: evidence for endorphinergic mediation. The role of peptides and amino-acids as neurotransmitters. Alan R. Liss Inc., New York 1981; 161–169
- Volavka J., Cho D., Mallya A. Naloxone increases ACTH and cortisol levels in man. New England Journal of Medicine 1979; 300: 1056–1057
- Wakabayashi I., Demura R., Miki N., Ohmura E., Miydshi A., Shizume K. Failure of naloxone to influence plasma GH, prolactin and cortisol release induced by insulin hypoglycaemia. Journal of Clinical Endocrinology and Metabolism 1980; 50: 597–599